Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

• Status: Completed
• Trial end date: 2009-08-28
• Target enrollment: 0
• Participant gender: Male

Summary

GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study drug gets into the brain. This will be done using Positron Emission Tomography (PET).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Generally healthy.

• Male between 35 and 55 years of age.

• Willing to use appropriate contraception method.

• Weight more than 50 kg.

• BMI within the range 19 - 29 kg/m2.

• Adequate blood supply to the hand.

Exclusion Criteria:

• Abuse of drugs or alcohol.

• Smoker or history of regular use of tobacco- or nicotine-containing products in the past 6 months.

• ECG abnormality (personal or family history).

• Psychiatric disorder.

• Asthma or a history of asthma.

• Medical illness.

• Worked as a welder, metal worker or machinist.

• Suffers from claustrophobia or would be unable to lie still in a PET or MRI scanner for 1-2 hours.

• Has a cardiac pacemaker or other electrical device or ferromagnetic metal foreign bodies.

• Neurological disorder